{"brief_title": "Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients", "brief_summary": "The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.", "detailed_description": "Prior to initiation of study treatment all patients are screened and baseline lab values are taken. Patients then receive the study treatment, FORTOVASE, two times a day plus 2 new NRTI's. Assessments will be performed at specified intervals throughout the duration of treatment.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Saquinavir"], "criteria": "Inclusion Criteria You may be eligible for this study if you: - Are HIV-positive. - Have an HIV count of 5,000 copies/ml or more. - Have a CD4 count of 100 cells/mm3 or more. - Meet specific requirements if you have ever taken NRTIs. - Are 16 - 64 years old (need consent if under 18). - Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eligible for this study if you: - Have taken non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) for more than 2 weeks. - Have taken all the available NRTIs. - Have certain serious medical conditions, including severe liver disease or active opportunistic (AIDS-related) infection. - Have a history of weight loss, muscle pain, and loss of appetite. - Have taken certain medications, including anti-HIV drugs other than those required by this study. - Are pregnant or breast-feeding. - Abuse alcohol or drugs. - Are unable to complete the study for any reason.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "keyword": "Anti-HIV Agents", "mesh_term": ["HIV Infections", "Saquinavir"], "id": "NCT00002229"}